Conference Description

Registration is closed for this conference!

November 15, 2008
Cleveland Clinic Florida
Jagelman Conference Center
2950 Cleveland Clinic Blvd
Weston, Florida

Tell a friend about this conference

Release Date: November 15, 2008

Expiration Date: November 15, 2008

Estimated Time To Complete CME Activity: 7 Hours

Medium/Method: Live Conference

Hardware/Software Requirements: None

CME Credits: 7*

Nonrefundable registration fee: $0.

Target Audience: Physicians, Nurse Practitioners, and Physician Assistants.

Program Summary:
The focus of this CME activity is to provide an update in the prevention, diagnosis, and management of pulmonary disease to pulmonologists, hospitalists, and other health care providers who treat patients with pulmonary diseases. Current findings in pulmonary research in such topics as COPD, sepsis, asthma, bronchioectasis and adult cystic fibrosis, sarcoidosis, pulmonary hypertension, and alpha one anti-trypsin deficiency will be presented. Clinicians will benefit from learning new research findings that could lead to improved patient care and safety.

In planning this CME activity, the National Association for Continuing Education (NACE) performed a needs assessment. A literature search was conducted, national guidelines were reviewed, survey data was analyzed, and experts in each therapeutic area were consulted to determine gaps in practitioner knowledge, competence or performance. Learning objectives (see below), linked to identified gaps, were developed and will be addressed by each presenter.

This multidisciplinary program will utilize a variety of educational techniques incorporating the various aspects of Adult Learning Principles. There will be emphasis on audience participation utilizing interactive case-based presentations to deliver educational material. Participants will be asked to engage in pre and post testing to collect data for outcome studies and to uncover unmet needs for future programming.

Each participant will be provided with a syllabus containing presentations, clinical tools, and practical guidelines at the start of the program to be used for future reference.

Learning Objectives:
At the conclusion of this program, participants should be able to:

1. Discuss the philosophy of the new Asthma recommendations; Discuss the specific changes in the EPR
2. Identify the new recommendation in the surviving sepsis campaign; Describe the latest data on the interventions; Discuss implementation of the recommendation and best practices; Discuss methodology to prevent the emergence of resistant organisms; Discuss treatment of resistant pathogens
3. Describe the prevalence of the alpha one anti-trypsin deficency; Identify the novella approaches to increase testing; Discuss patient selection for treatment
4. *Explain the pathophysiology of Chronic Thromboembolic Disease; Describe workup of pulmonary hypertension and CTEPH; List therapeutic options in CTEPH and pulmonary hypertension
5. Discuss diagnosis of Sarcoidosis; Discuss when and who to treat; Discuss alternatives to steroids in advanced or refractory disease
6. Describe recent trials in COPD; Discuss evidence based treatment of COPD; Discuss measures to improve quality of life of COPD patients
7. Discuss pathophysiology of Bronchiectasis; Discuss the workup of bronchiectasis and Cystic Fibrosis; Discuss treatment of adult Cystic Fibrosis
8. Discuss common medical legal aspects of medicine in Florida; Describe how recent legislative changes may affect practice and how to prepare for it; Identify methods to avoid common mistakes when dealing with the Florida Statutes

Agenda:

7:30-8:00 am		Continental Breakfast and Registration
8:00-8:10		Welcome Remarks and Pre-Test Franck Rahaghi, MD
8:10-9:00		Asthma: Applying the New Guidelines Frank Eidelman, MD
9:00-9:50		Surviving Sepsis: What Is The Latest Consensus? R. P. Dellinger, MD
9:50-10:20		Break/Vendor Area
10:20-11:10		Alpha one Anti-trypsin Deficiency: Future of testing Franck Rahaghi, MD
11:10-12:00		*Advances in Pulmonary Hypertension and Chronic Thromboembolic Disease Victor Tapson, MD
12:00-1:10		Lunch
1:10-2:00		Advances in the Treatment of Sarcoidosis Alvin S. Teirstein, MD
2:00-2:50		COPD: What Is The Evidence? Charlie Strange, MD
2:50-3:10		Break/Vendor area
3:10-4:00		Bronchiectasis and Adult Cystic Fibrosis: Diagnosis and Management Scott Donaldson, MD
4:00-4:50		Medical-Legal and Regulatory Aspects of Medicine: What You Need To Know Eduardo Oliveira, MD
4:50-5:00		Closing Remarks and Post-Test Franck Rahaghi, MD, MHS

Faculty:
R. P. Dellinger, MD
Head, Division of Critical Care Medicine
Cooper University Hospital, Camden, NJ
(Surviving Sepsis Campaign)

Scott Donaldson, MD
Assistant Professor of Medicine
University of North Carolina, Chapel Hill, NC

Frank Eidelman, MD
Chairman of Department
Allergy and Immunology
Cleveland Clinic Florida, Weston, FL

Eduardo Oliveira, MD
Chair, Division of Medicine
Pulmonary and Critical Care Department
Cleveland Clinic Florida, Weston, FL

Franck Rahaghi, MD
Director of Pulmonary Hypertension Clinic,
Head, Pulmonary Education and Rehabilitation
Chair of Quality
Cleveland Clinic Florida, Weston, FL

Charlie Strange, MD
Professor of Pulmonary Medicine
Division of Pulmonary and Critical Care Medicine
Medical University of South Carolina
Charleston, SC

Victor Tapson, MD
Division of Pulmonary and Critical Care Medicine
Duke University Medical Center, Durham, NC
(ACCP Consensus Statement on Antithrombotic Therapy)

Alvin S. Teirstein, MD
Professor of Medicine, Mount Sinai
College of Medicine, New York, NY
(Master Clinician, Mt. Sinai Sarcoidosis Laboratories)

Program Chair: Franck Rahaghi, MD, MHS, FCCP

Activity Director: Michelle Frisch, MPH

*Continuing Education Information
This activity has been reviewed and is acceptable for up to 7.00 Prescribed credits by the American Academy of Family Physicians.

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The National Association for Continuing Education designates this educational activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

*This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School (UMMS) and the National Association for Continuing Education. The University of Massachusetts Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Massachusetts Medical School designates this educational activity for a maximum of 1 AMA PRA Category I Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure: It is the policy of the University of Massachusetts Medical School and the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School and the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

This activity is supported by educational donations provided by: Astellas, Actelion, Boehringer Ingelheim, CSL Behring, Genentech, Gilead, Merck, Sepracor, Talecris Biotherapuetics, and United Therapeutics.